Myriad Genetics, Inc. is discontinuing development of tarenflurbil, also known as Flurizan, after the investigational treatment for Alzheimer’s disease failed to achieve significance on the co-primary endpoints – cognition and activities of daily living, of a Phase III trial.
From our partners at VerusMed:
Verusmed.com
Sponsored by The Doctor’s Channel
